Healthtech funding in Q1 2019
European Healthtech startup funding raised during Q1 2019.
In Q1 2019, 115 European Healthtech companies closed 115 funding rounds and raised €1.3B in equity funding (excluding debt and grants), down 16.4% versus Q1 2018. France led by capital raised, and Balderton Capital was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.3B
-16.4% vs Q1 2018 · excl. debt & grants
Funding rounds
115
-40.1% vs Q1 2018
Companies
115
Top country
France
Rank among sectors
#3
12.1% of sector funding
Top-10 round share
43.1%
of disclosed capital
Rounds ≥ €100M
1
Top countries
by € raisedHealthtech — top countries by capital, Q1 2019 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2019 | |
|---|---|
| France | €301M |
| Israel | €279M |
| UK | €162M |
| Switzerland | €150M |
| Ireland | €86M |
| Denmark | €60M |
| Germany | €54M |
| Iceland | €44M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2019 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2019 | |
|---|---|
| Other | €346M |
| Series B | €276M |
| Series A | €269M |
| Series D+ | €251M |
| Series C | €105M |
| Seed | €42M |
Exits & M&A
7 Acquisition · 2 IPO9 exits · €524M disclosed.
| InMode | IPO | Feb 2019 | €384M |
| Nutrino | Acquisition | Jan 2019 | €91M |
| Sequana Medical | IPO | Jan 2019 | €28M |
| Bokadirekt | Acquisition | Jan 2019 | €21M |
Top deals
largest disclosed rounds in Q1 2019| Company | Stage | Date | Amount |
|---|---|---|---|
| Doctolib | Series D+ | Jan 2019 | €150M |
| Sophia Genetics | Series D+ | Jan 2019 | €67M |
| Inivata | Series B | Jan 2019 | €46M |
| Vivet Therapeutics | Other | Jan 2019 | €45M |
| DentalMonitoring | Other | Jan 2019 | €45M |
| Snipr Biome | Series A | Jan 2019 | €44M |
| Alvotech | Other | Jan 2019 | €44M |
| Syqe Medical | Other | Jan 2019 | €44M |
| Atai Life Sciences | Series B | Jan 2019 | €38M |
| EarlySense | Series D+ | Jan 2019 | €34M |
| HighLife | Series B | Jan 2019 | €32M |
| Anaveon | Series A | Jan 2019 | €31M |
| Theranica | Series B | Jan 2019 | €31M |
| Atlantic Therapeutics | Series B | Jan 2019 | €28M |
| BiomX | Series B | Jan 2019 | €28M |
Top investors
most active in Q1 2019, by deal count- Balderton Capital3 deals
- aMoon Fund2 deals
- Felix Capital2 deals
- High-Tech Gründerfonds (HTGF)2 deals
- Horizon 20202 deals
- INKEF Capital2 deals
- Innovate UK2 deals
- Repair Impact Fund2 deals
- Sophia Bendz2 deals
- 24Haymarket1 deals